Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
NCT00427583
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
11
Enrollment
INDUSTRY
Sponsor class
Stopped
stopped due to slow recruitment and no effect
Conditions
Malignant Peripheral Nerve Sheath Tumors
Interventions
DRUG:
imatinib mesylate
Sponsor
Novartis Pharmaceuticals